LOW-DOSE METRONOMIC TEMOZOLOMIDE AND SORAFENIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME: A PHASE II CLINICAL TRIAL WITH EVALUATION OF CLINICAL, BIOLOGIC AND PHARMACODYNAMIC EFFECTS OF THE COMBINATION
Latest Information Update: 19 Dec 2013
At a glance
- Drugs Sorafenib (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms GLIMESOR
- 29 Aug 2012 New trial record